CD34 and acute myeloid leukemia: In this scenario, considering that AML arises from the hematopoietic stem cell, and that more than 90% of AML blasts express CD34 antigen, an option to monitor if allo-SCT has been able to cancel autologous hemopoiesis is the assessment of molecular chimerism on CD34+ cells (14–17).